Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Misses Revenue Estimates

Company Performance - Kymera Therapeutics reported a quarterly loss of $0.95 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.83, and compared to a loss of $0.58 per share a year ago, indicating a significant decline in performance [1] - The company posted revenues of $11.48 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 66.7%, and down from $25.65 million in the same quarter last year [2] - Over the last four quarters, Kymera has surpassed consensus EPS estimates only two times and topped revenue estimates just once [2] Market Comparison - Kymera Therapeutics shares have increased by about 1% since the beginning of the year, while the S&P 500 has gained 8.6%, indicating underperformance relative to the broader market [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.92 on revenues of $16.74 million, and for the current fiscal year, it is -$3.39 on revenues of $80.99 million [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the bottom 41% of over 250 Zacks industries, suggesting that the industry outlook may negatively impact stock performance [8] Estimate Revisions - The estimate revisions trend for Kymera Therapeutics was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6]